Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature.

医学 心房颤动 拜瑞妥 内科学 达比加群 心脏病学 依杜沙班 阿哌沙班 华法林 抗血栓 直接凝血酶抑制剂 重症监护医学
作者
Filipe Ferrari,Anderson Donelli da Silveira,Vitor Magnus Martins,Leandro Tolfo Franzoni,Leandro Ioschpe Zimerman,Ricardo Stein
出处
期刊:Cardiology in Review [Lippincott Williams & Wilkins]
卷期号:29 (3): 120-130 被引量:3
标识
DOI:10.1097/crd.0000000000000312
摘要

Atrial fibrillation (AF) is considered the most common sustained cardiac arrhythmia, and it is associated with a significant risk of adverse events, especially ischemic stroke. Oral anticoagulation is the cornerstone for stroke prevention in AF; for many years, only vitamin K antagonists were used for this purpose, with an absolute risk reduction >60% for. However, these agents have limitations, such as narrow therapeutic margins and drug-food and drug-drug interactions. More recently, four direct-acting oral anticoagulants (DOACs) - non-vitamin K antagonists - have become available for patients with AF: dabigatran, rivaroxaban, apixaban, and edoxaban. In addition to a comparable efficacy to warfarin in large randomized controlled trials, DOACs were found to promote a lower risk of intracranial bleeding. The strategic dosage and lack of need for periodic prothrombin-time testing makes their use attractive, especially for primary or secondary prevention of stroke in older adults. Furthermore, among patients with AF presenting with acute coronary syndrome or undergoing percutaneous coronary intervention, apixaban is associated with a reduction in serious bleeding events when compared to warfarin. On the other hand, there is no evidence of benefit of DOACs in patients with mechanical prosthetic valves or moderate/severe mitral stenosis. Furthermore, the suitability of DOACs in patients with liver disease is still poorly understood, and their safety in patients requiring renal replacement therapy remains uncertain. This review provides an overview of the main trials of DOACs, their pharmacology and safety profile, clinical implications, and best indications in light of the current evidence.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yixi完成签到,获得积分20
刚刚
xiaxng发布了新的文献求助10
刚刚
刚刚
olivia完成签到,获得积分10
1秒前
TTOM完成签到,获得积分10
1秒前
Rrr发布了新的文献求助10
1秒前
2秒前
Usting完成签到,获得积分10
2秒前
2秒前
3秒前
爆米花的应助被momo采纳,获得10
3秒前
enuiu完成签到,获得积分10
3秒前
3秒前
4秒前
极限001的应助被kaiyang采纳,获得200
4秒前
h11的应助被欧皇采纳,获得10
4秒前
绵马紫萁发布了新的文献求助10
4秒前
01完成签到 ,获得积分10
4秒前
姚青筠发布了新的文献求助10
4秒前
4秒前
布丁完成签到,获得积分10
5秒前
5秒前
5秒前
阿桐木完成签到 ,获得积分10
6秒前
wz1666完成签到,获得积分10
6秒前
WY发布了新的文献求助10
6秒前
云汐完成签到,获得积分10
6秒前
完美世界的应助被飞飞飞采纳,获得10
7秒前
木木完成签到 ,获得积分10
8秒前
8秒前
kongxz发布了新的文献求助10
8秒前
戴帽子的花盆完成签到,获得积分10
8秒前
8秒前
fortuna发布了新的文献求助10
8秒前
所所的应助被不辣的皮特采纳,获得10
8秒前
天天开心发布了新的文献求助10
9秒前
Victor发布了新的文献求助10
9秒前
9秒前
hcf_yicheng发布了新的文献求助30
9秒前
sunnymoon发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161749
求助须知:如何正确求助?哪些是违规求助? 9556240
关于积分的说明 21733360
捐赠科研通 7751657
什么是DOI,文献DOI怎么找? 3427566
关于科研通互助平台的介绍 2552632
邀请新用户注册赠送积分活动 2472047